A Anil Timur1, Gurunathan Murugesan1, Li Zhang2, John Barnard2, Deepak L Bhatt3, Kandice Kottke-Marchant4. 1. Robert J. Tomsich Pathology and Laboratory Medicine Institute, Cleveland Clinic, Cleveland, OH, USA. 2. Quantitative Health Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA. 3. Brigham and Women's Hospital Heart & Vascular Center, and Harvard Medical School, Boston, MA, USA. 4. Robert J. Tomsich Pathology and Laboratory Medicine Institute, Cleveland Clinic, Cleveland, OH, USA. Electronic address: marchak@ccf.org.
Abstract
INTRODUCTION: Poor response to antiplatelet drugs is associated with adverse outcomes. We assessed platelet inhibition and its stability and tested correlation and agreement between platelet function assays. METHODS: Peripheral blood from 58 patients on both aspirin and clopidogrel who underwent percutaneous coronary intervention (PCI) was collected at hospital discharge (visit-1) and at 30-90 days (visit-2). Platelet function was measured using light transmission aggregometry (LTA-AA and LTA-ADP), VerifyNow® (Aspirin; ARU and P2Y12; PRU), ex vivo TxB2, urinary 11dhTxB2, and VASP (PRI) assays. Data were analyzed as continuous, quartiles and binary. Patients were defined as aspirin poor responder (PR) with ARU ≥ 550, LTA-AA maximum ≥ 20%, TxB2 ≥ 1 ng/mL or 11dhTxB2 ≥ 1,500 pg/mg of creatinine and as clopidogrel PR with PRU ≥ 240, PRU ≥ 208, LTA-ADP maximum ≥ 40%, PRI ≥ 50%, or PRI ≥66%. RESULTS: Aspirin PR was 3-33% and clopidogrel PR was 10-35% in visit-1. LTA-AA, 11dhTxB2, and all clopidogrel-response measures showed correlation and agreement between visit-1 and visit-2. The highest agreement between two visits was revealed by PRU ≥ 240 and PRI ≥ 66% (PRU-κ=0.7, 95% CI=0.47, 0.93; PRI-κ=0.69, 95% CI=0.42, 0.95, p-values<0.001). Comparison of platelet function assays in a single visit (visit-1) revealed a poor correlation between LTA-AA and 11dhTxB2 assays and no agreement among aspirin-response assays. The highest correlation and agreement were obtained between VerifyNow® P2Y12 and VASP assays (rho=0.7, p-value<0.001 and PRU ≥ 208-PRI-κ=0.41-0.42, 95% CI=0.13, 0.69, p-values<0.001). CONCLUSIONS: Platelet inhibition is stable during aspirin and clopidogrel treatment. Clopidogrel-response assays correlate and agree with each other better than aspirin-response assays.
INTRODUCTION: Poor response to antiplatelet drugs is associated with adverse outcomes. We assessed platelet inhibition and its stability and tested correlation and agreement between platelet function assays. METHODS: Peripheral blood from 58 patients on both aspirin and clopidogrel who underwent percutaneous coronary intervention (PCI) was collected at hospital discharge (visit-1) and at 30-90 days (visit-2). Platelet function was measured using light transmission aggregometry (LTA-AA and LTA-ADP), VerifyNow® (Aspirin; ARU and P2Y12; PRU), ex vivo TxB2, urinary 11dhTxB2, and VASP (PRI) assays. Data were analyzed as continuous, quartiles and binary. Patients were defined as aspirin poor responder (PR) with ARU ≥ 550, LTA-AA maximum ≥ 20%, TxB2 ≥ 1 ng/mL or 11dhTxB2 ≥ 1,500 pg/mg of creatinine and as clopidogrel PR with PRU ≥ 240, PRU ≥ 208, LTA-ADP maximum ≥ 40%, PRI ≥ 50%, or PRI ≥66%. RESULTS:Aspirin PR was 3-33% and clopidogrel PR was 10-35% in visit-1. LTA-AA, 11dhTxB2, and all clopidogrel-response measures showed correlation and agreement between visit-1 and visit-2. The highest agreement between two visits was revealed by PRU ≥ 240 and PRI ≥ 66% (PRU-κ=0.7, 95% CI=0.47, 0.93; PRI-κ=0.69, 95% CI=0.42, 0.95, p-values<0.001). Comparison of platelet function assays in a single visit (visit-1) revealed a poor correlation between LTA-AA and 11dhTxB2 assays and no agreement among aspirin-response assays. The highest correlation and agreement were obtained between VerifyNow® P2Y12 and VASP assays (rho=0.7, p-value<0.001 and PRU ≥ 208-PRI-κ=0.41-0.42, 95% CI=0.13, 0.69, p-values<0.001). CONCLUSIONS: Platelet inhibition is stable during aspirin and clopidogrel treatment. Clopidogrel-response assays correlate and agree with each other better than aspirin-response assays.
Authors: Matthew J Price; Dominick J Angiolillo; Paul S Teirstein; Elizabeth Lillie; Steven V Manoukian; Peter B Berger; Jean-François Tanguay; Christopher P Cannon; Eric J Topol Journal: Circulation Date: 2011-08-29 Impact factor: 29.690
Authors: Paul A Gurbel; Kevin P Bliden; Jorge F Saucedo; Thomas A Suarez; Joseph DiChiara; Mark J Antonino; Elisabeth Mahla; Anand Singla; William R Herzog; Ashwani K Bassi; Thomas A Hennebry; Tania B Gesheff; Udaya S Tantry Journal: J Am Coll Cardiol Date: 2009-02-24 Impact factor: 24.094
Authors: Brian K Jefferson; Jennifer H Foster; Jeanette J McCarthy; Geoffrey Ginsburg; Alex Parker; Kandice Kottke-Marchant; Eric J Topol Journal: Am J Cardiol Date: 2005-03-15 Impact factor: 2.778
Authors: Paul Harrison; Helen Segal; Louise Silver; Anila Syed; Fiona C Cuthbertson; Peter M Rothwell Journal: Platelets Date: 2008-03 Impact factor: 3.862
Authors: Marie Lordkipanidzé; Chantal Pharand; Erick Schampaert; Jacques Turgeon; Donald A Palisaitis; Jean G Diodati Journal: Eur Heart J Date: 2007-06-14 Impact factor: 29.983